Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

Phase 2

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Doxycyclin

First Posted Date: 2024-06-11

Last Posted Date: 2024-07-03

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 50

Registration Number: NCT06452394

Locations: 🇨🇭
Kantonsspital St.Gallen, St. Gallen, SG, Switzerland
🇨🇭
Clinique de Genolier, Genolier, VD, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, GR, Switzerland

and more 4 locations

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Other: Standard of care
Drug: Darolutamide

First Posted Date: 2024-05-07

Last Posted Date: 2024-10-24

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 162

Registration Number: NCT06401980

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Switzerland

and more 8 locations

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase 2

Recruiting

Conditions: Triple-negative Breast Cancer
TNBC - Triple-Negative Breast Cancer

Interventions: Drug: INT230-6
Other: neoadjuvant immuno-chemotherapy

First Posted Date: 2024-04-10

Last Posted Date: 2024-11-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 54

Registration Number: NCT06358573

Locations: 🇨🇭
Tumor Zentrum Aarau, Aarau, Switzerland
🇨🇭
St. Claraspital, Basel, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

and more 6 locations

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Not Applicable

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)
Stage IV

Interventions: Other: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
Radiation: Radiotherapy
Other: Surgery

First Posted Date: 2023-11-02

Last Posted Date: 2024-05-31

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 128

Registration Number: NCT06114108

Locations: 🇨🇭
Luzerner Kantonsspital, Luzern, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Hôpital Fribourgeois - Hôpital Cantonal, Fribourg, Switzerland

and more 5 locations

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Not Applicable

Recruiting

Conditions: Non-hodgkin Lymphoma, B Cell

Interventions: Diagnostic Test: ctDNA detection

First Posted Date: 2023-10-19

Last Posted Date: 2024-03-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 64

Registration Number: NCT06090162

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Kantonspital Aarau, Aarau, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

and more 10 locations

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Docetaxel micellar

First Posted Date: 2020-11-16

Last Posted Date: 2024-08-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 11

Registration Number: NCT04629781

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
IOSI - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
Drug: Atezolizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2020-11-16

Last Posted Date: 2024-03-12

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT04630730

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Klinik Hirslanden - Onkozentrum Hirslanden, Zürich, Switzerland
🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland

and more 7 locations

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2020-10-27

Last Posted Date: 2024-12-09

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 260

Registration Number: NCT04604067

Locations: 🇮🇹
Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
Azienda Ospedaliera Universitaria Maggiore della Carita di Novara, Novara, Italy
🇮🇹
Policlinico Agostino Gemelli, Roma, Italy

and more 16 locations

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma
Non-small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Atezolizumab

First Posted Date: 2020-07-21

Last Posted Date: 2024-07-01

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 68

Registration Number: NCT04480372

Locations: 🇨🇭
HFR Fribourg, Fribourg, Villars-sur-Glâne, Switzerland
🇨🇭
St. Claraspital, Basel, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland

and more 9 locations

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2

Active, not recruiting

Conditions: Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Durvalumab
Drug: carboplatin
Drug: etoposide
Radiation: Thoracic radiotherapy

First Posted Date: 2020-07-16

Last Posted Date: 2023-09-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT04472949

Locations: 🇨🇭
Spital Männedorf, Männedorf, Switzerland
🇨🇭
Regionalspital Thun, Thun, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

and more 11 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy